Livforsakringsbolaget Skandia Omsesidigt reduced its stake in Johnson & Johnson (NYSE:JNJ) by 36.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 180,520 shares of the company’s stock after selling 105,200 shares during the period. Johnson & Johnson accounts for 2.1% of Livforsakringsbolaget Skandia Omsesidigt’s holdings, making the stock its 3rd largest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Johnson & Johnson were worth $22,484,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Glenview Trust Co acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $18,192,000. RBO & Co. LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $24,734,000. Capital Analysts LLC increased its stake in shares of Johnson & Johnson by 6.6% in the fourth quarter. Capital Analysts LLC now owns 24,731 shares of the company’s stock valued at $2,849,000 after buying an additional 1,522 shares during the period. CWA Asset Management Group LLC increased its stake in shares of Johnson & Johnson by 13.1% in the fourth quarter. CWA Asset Management Group LLC now owns 55,685 shares of the company’s stock valued at $6,415,000 after buying an additional 6,451 shares during the period. Finally, Amtrust Financial Services Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $1,151,000. 66.10% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) traded down 0.31% during midday trading on Friday, reaching $132.63. The company’s stock had a trading volume of 4,661,630 shares. The stock’s 50-day moving average is $132.88 and its 200-day moving average is $126.90. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a market capitalization of $355.98 billion, a P/E ratio of 22.44 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same period last year, the business posted $1.74 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
TRADEMARK VIOLATION WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/08/18/livforsakringsbolaget-skandia-omsesidigt-decreases-stake-in-johnson-johnson-jnj-updated-updated-updated.html.
JNJ has been the topic of several recent analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 target price on the stock in a research note on Monday, April 24th. Jefferies Group LLC reissued a “hold” rating and set a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. J P Morgan Chase & Co raised Johnson & Johnson from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $123.64 to $140.00 in a research note on Monday, May 15th. UBS AG restated a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Finally, Stifel Nicolaus restated a “hold” rating and set a $128.00 price target (up previously from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $134.12.
In related news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
